Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

HIV Testing Increased and Infection Reduced in Africa with Community Intervention

Published: Thursday, March 07, 2013
Last Updated: Wednesday, March 06, 2013
Bookmark and Share
Free mobile HIV testing and counseling, same-day results and post-test support reduces HIV infections by 14 percent.

Community intervention with free mobile HIV testing and counseling, same-day results and post-test support led to a 14 percent reduction in new HIV infections in targeted communities in Sub-Saharan Africa, according to results of a large randomized, controlled trial.

In women between the ages of 25 and 32, the intervention showed an even greater effect, with rates of new infections lowered by almost one-third.

The trial, National Institute of Mental Health “Project Accept” (HIV Prevention Trial Network 043), was conducted in 48 communities at five sites in Zimbabwe, Tanzania, South Africa and Thailand.

The study was undertaken by UC San Francisco at the Zimbabwe site in collaboration with the University of Zimbabwe.

The trial sought to demonstrate a community-level impact on HIV when proven prevention interventions were taken to scale. A primary goal was to increase awareness of HIV status by decreasing barriers to testing.

“HIV testing increased by a quarter overall and we saw a four-fold increase in the detection of new HIV cases at the Sub-Saharan sites.” said Stephen F. Morin, PhD, co-principal investigator of the multi-institution trial and professor of medicine at the UCSF Center for AIDS Prevention Studies.

Morin continued, “The trial was particularly effective in increasing HIV testing among men. At baseline, women were far more likely to have been tested than men and the intervention increased their testing by 15 percent. However, the study’s success in substantially increasing HIV testing in men, by 45 percent, erased the gender gap.”

In addition, Morin said, the trial found that men who learned they were infected reduced their overall number of sexual partners by one-fifth and reduced their concurrent partnerships by almost one-third.

Many epidemiological studies have identified concurrent partnerships as a major impetus for high rates of HIV infections in Sub-Saharan Africa.

“The trial demonstrated that a well designed and implemented intervention can change behavior that leads to an effect at a community level. We were particularly successful in changing behavior in men after they learned they were infected, and we saw the impact in the sharp reduction in the rate of new infections in women in the intervention communities,” said Morin.

The results of the trial were presented at the Conference on Retroviruses and Opportunistic Infections in Atlanta.

Multilayer Intervention Efforts
The trial was conducted over a 36-month period and involved large numbers of participants: 33,774 households were visited by field teams at baseline and 84,947 were visited at the post-intervention assessment. All of the sites, except Soweto, South Africa, were predominately rural. The Chiang Mai, Thailand, site was notable for the very low percentage of people in the community living with HIV - less than 1 percent.

Community mobilization activities included dispatching outreach workers and community-based volunteers door-to-door, holding large community meetings and the creation of “community working groups,” composed of local leaders who assisted in developing plans to increase utilization of testing services.

Testing was provided either at community sites or by mobile vans and provided same-day results. Counseling included individualized risk reduction assessments and referrals to a variety of local services.

Extensive post-test support services were delivered to individuals who tested positive. These included individual counseling, information sharing sessions, support groups, coping effectiveness workshops and/or stigma reduction workshops.

The UCSF Center for AIDS Prevention Studies served as the Intervention Core for the multisite study. The Intervention Core was responsible for the actual implementation of the different components over the 36-month duration of the trial.

For the successful implementation of a trial based upon community mobilization, a key element was to create and sustain a supportive environment in the community.

At the time Project Accept started, many communities had little or no access to HIV testing and stigma was pervasive.

“We built strong relationships with community leaders and elders, which was essential in rural settings. We also engaged the early adopters of the intervention as community outreach volunteers. Living in the community and accessible to the community for questions, they also provided us with feedback as to what the community was thinking and that allowed us to adapt the intervention to better fit each community,” said Gertrude Khumalo-Sakutukwa, MSSW, MMS, director of the Intervention Core and research specialist at the UCSF Center for AIDS Prevention Studies.

David Celentano from Johns Hopkins University, Michael Sweat from the Medical University of South Carolina and Thomas J. Coates from UCLA were co-principal investigators of the trial. Sten Vermund and Wafaa El-Sadr are the principal investigators of the HIV Prevention Trials Network.

Project Accept was funded by the U.S. National Institute of Mental Health and through the HIV Prevention Trials Network as HPTN 043 by the Division of AIDS of the U.S. National Institute of Allergy and Infectious Diseases and by the Office of AIDS of the U.S. National Institutes of Health.

The UCSF Center for AIDS Prevention Studies is affiliated with the AIDS Research Institute (ARI) at UCSF.

UCSF ARI houses hundreds of scientists and dozens of programs throughout UCSF and affiliated labs and institutions, making ARI one of the largest AIDS research entities in the world.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Thursday, August 20, 2015
Type 1 Diabetes Drug Proves Effective in Clinical Trial
Drug developed by UCSF researcher shows promise for blocking advance of disease in earliest stages.
Thursday, August 08, 2013
Researchers Identify Protein Key in Proliferation of Lymphoma Cells
Inhibiting PERK protein could reduce formation of cancerous tumors.
Thursday, November 29, 2012
Heart Failure Drug Shows Promise in Phase III Clinical Trial
Results were presented by John Teerlink at the American Heart Association’s Scientific Sessions 2012.
Monday, November 12, 2012
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos